OrPro Therapeutics Inc

OrPro Therapeutics Inc

Developing a breakthrough class of inhaled, non-systemic drugs for treatment of Cystic Fibrosis and other obstructive pulmonary diseases characterized by thickened, abnormal mucus.

Area of focus: 
Immunology
Commencement date: 
01/08/2014

Share